Filter Results:
(1,248)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- 17 Mar 2009
- First Look
First Look: March 17, 2009
Agreements in Bio-Pharmaceuticals Authors:Juan Alcácer, John Cantwell, and Michelle Gittelman Publication:In Location of Biopharmaceutical Activity, edited by Iain M. Cockburn and Matthew J. Slaughter. NBER, forthcoming. Abstract As the value chain of the View Details
Keywords: Martha Lagace
- 24 Oct 2016
- News
Health Care Pioneer Giusti Named McCance Senior Fellow at HBS
care, or engineering. Giusti currently serves as faculty cochair of the HBS-Kraft Precision Medicine Accelerator. She has more than two decades of experience in the pharmaceutical industry, having previously held senior positions at G. D.... View Details
Keywords: Susan Young
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
specified stage of development. It would throw the ball over the fence [to a major pharmaceutical firm] and it would sit around and wait. Sooner or later, if the product was successful, it would collect some royalties." Now, a... View Details
- Profile
Evan Rachlin
experienced as a medical student, business issues are an inescapable reality for any physician. While shadowing a pediatrician in private practice, he noticed the tension between the busy physician and a pharmaceutical representative... View Details
- 01 Dec 2003
- News
Alumni Luminaries Discuss Careers, Values with HBS Students
Internal Revenue Service. Senior advisor, The Carlyle Group. He upgraded technology and information systems and stressed customer service in a dramatic turnaround of the IRS. Daniel L. Vasella, M.D. (PMD 57, 1989), chairman and CEO of Novartis AG, the world’s... View Details
- 01 Mar 2017
- News
How Deep Brain Stimulation Could Change Medicine
pharmaceuticals are the primary choice,” says Bennet. “But in most cases they’re not really a miracle” but a temporary reprieve. Bennet notes that while millions of patients suffer from psychiatric disorders, many don’t know that deep... View Details
Keywords: Janelle Nanos
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs what kinds of services. These things are all connected, and changing one piece, or plugging an... View Details
- 01 Mar 2009
- News
A New Approach to Health-Care Reform
approach not just to insurance and reimbursement, but also to the places where medical services are delivered, the way we use technology, the way pharmaceuticals are developed, the way we educate medical professionals, and who performs... View Details
- 23 Jun 2003
- Research & Ideas
Historically Speaking: A Roundtable at HBS
States, Europe, and Japan, it was supposed to examine two sectors: first, the chemical and pharmaceutical industries, which helped bring about the Second Industrial Revolution between the 1880s and 1920s, and second, consumer electronics... View Details
Keywords: by Jim Aisner
- 13 Aug 2019
- Blog Post
What is the MS/MBA Biotechnology: Life Sciences Program?
biotechnology and pharmaceutical experience, and will provide a distilled and focused exposure to a wide range of modern science and how it can be deployed for discovery of novel therapeutics. The Master of Business Administration (MBA)... View Details
- Student-Profile
Byungyeon Kim
important Harvard’s worldwide research centers would be to his work. His second year research project involved a study of sales force compensation that resulted from a partnership with a Turkish pharmaceutical company made possible by an... View Details
- 01 Sep 2020
- Cold Call Podcast
How to Launch a New Biosciences Product: Start Small or Dive in?
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States
Tufano, Peter, Geoffrey Verter, and Markus Mullarkey. "Cephalon, Inc." Harvard Business School Case 298-116, April 1998.
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- April 2017
- Supplement
Imprimis (D)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details
Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
- December 1999 (Revised January 2000)
- Case
Agrochemicals at Ciba-Geigy AG (B)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
Focuses on Pierre Urech's efforts to change the division structure at Ciba-Geigy to facilitate the marketing of the new product. Details the relationships Urech cultivates and the strategy he pursues as "product champion." Also describes the restructuring of the... View Details
Keywords: Change Management; Innovation Strategy; Innovation and Management; Leadership Development; Leadership Style; Research and Development; Marketing Strategy; Goods and Commodities; Product Development; Pharmaceutical Industry; Switzerland
Tushman, Michael L., Wendy Smith, and Daniel Radov. "Agrochemicals at Ciba-Geigy AG (B)." Harvard Business School Case 400-023, December 1999. (Revised January 2000.)